Related Experiment Video
Updated: Aug 7, 2026
11:06
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Published on: January 31, 2022
Stevens-Johnson syndrome associated with glipizide therapy
Jeffrey B Cheng1, Robert C Anderson, Ponciano D Cruz
1Department of Dermatology, The University of Texas Southwestern Medical Center, Dallas, TX 52390-9069, USA.
Dermatitis : Contact, Atopic, Occupational, Drug
|June 28, 2006
Summary
A patient developed Stevens-Johnson syndrome (erythema multiforme major) after an increased glipizide dosage. This is the first reported case linking a second-generation sulfonylurea drug to this severe adverse reaction.
Area of Science:
- Pharmacology
- Dermatology
- Endocrinology
Background:
- Glipizide is a widely prescribed second-generation sulfonylurea for managing non-insulin-dependent diabetes mellitus.
- Stevens-Johnson syndrome (SJS) is a severe mucocutaneous adverse drug reaction.
- Previous reports have linked SJS to first-generation sulfonylureas.
Observation:
- A case study detailing a patient experiencing Stevens-Johnson syndrome (erythema multiforme major).
- The adverse reaction was observed following an increase in the dosage of glipizide.
- This patient was being treated for non-insulin-dependent diabetes mellitus.
Findings:
- This case represents the first documented instance of Stevens-Johnson syndrome associated with a second-generation sulfonylurea, specifically glipizide.
- The findings highlight a potential risk previously unreported for this class of diabetes medication.
Implications:
- Clinicians should be aware of the potential for Stevens-Johnson syndrome with glipizide, particularly upon dosage adjustments.
- This case may prompt further investigation into the association between second-generation sulfonylureas and severe cutaneous adverse reactions.
- Enhanced pharmacovigilance for glipizide and similar medications is warranted to identify and mitigate risks.
Related Concept Videos
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
01:25Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.